Canadian journal of physiology and pharmacology

Incretin Treatments for Obesity: Current and Future Drug Options

Updated

Abstract

Incretin-targeted therapies may provide a promising approach to obesity management.

  • Obesity is influenced by a combination of metabolic, environmental, and psychosocial factors.
  • Key hormones, such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), amylin, and glucagon, play crucial roles in energy balance, appetite regulation, and insulin secretion.
  • Emerging therapies include dual and triple receptor agonists that target these hormones.
  • Future developments may focus on personalized medicine, including innovative drug-delivery systems and new therapeutic targets.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The corresponding author serves as a speaker for Eli Lilly on Zepbound. This financial relationship has been managed in accordance with the ethical standards and policies of the journal. The views expressed in this review are solely those of the author and are not reflective of the positions of Eli Lilly. The other authors do not have any relevant or financial disclosures.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free